These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Delavirdine: a review of its use in HIV infection. Scott LJ; Perry CM Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019 [TBL] [Abstract][Full Text] [Related]
5. Adverse effects of chronic treatment with the Main subclasses of highly active antiretroviral therapy: a systematic review. Silva BF; Peixoto G; da Luz SR; de Moraes S; Peres SB HIV Med; 2019 Aug; 20(7):429-438. PubMed ID: 31006976 [TBL] [Abstract][Full Text] [Related]
6. [Role of etravirine in combination antiretroviral therapy]. Domingo P Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628 [TBL] [Abstract][Full Text] [Related]
7. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). De Clercq E Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005 [TBL] [Abstract][Full Text] [Related]
8. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Barbaro G; Di Lorenzo G; Cirelli A; Grisorio B; Lucchini A; Hazra C; Barbarini G Clin Ther; 2003 Sep; 25(9):2405-18. PubMed ID: 14604740 [TBL] [Abstract][Full Text] [Related]
9. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience. Joly V; Yeni P Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761 [TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1: drug resistance in treated and untreated Brazilian children. Simonetti SR; Schatzmayr HG; Simonetti JP Mem Inst Oswaldo Cruz; 2003 Sep; 98(6):831-7. PubMed ID: 14595464 [TBL] [Abstract][Full Text] [Related]
11. [Hypersensitivity reactions to antiretroviral agents in HIV-infected patients]. Marcos Bravo MC; Ocampo Hermida A; Moreno Rodilla E Med Clin (Barc); 2007 Jan; 128(2):61-9. PubMed ID: 17266904 [TBL] [Abstract][Full Text] [Related]
12. [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors]. Bonora S; Calcagno A; Gonzalez de Requena D; Bargiacchi O; Di Perri G Infez Med; 2006 Jun; 14(2):61-70. PubMed ID: 16891850 [TBL] [Abstract][Full Text] [Related]
13. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond. Murphy RL AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous toxicities of antiretroviral therapy for HIV: part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome. Introcaso CE; Hines JM; Kovarik CL J Am Acad Dermatol; 2010 Oct; 63(4):563-9; quiz 569-70. PubMed ID: 20846564 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of adverse events associated with antiretroviral therapy and the relationship to treatment adherence. Lenzi L; Wiens A; Pontarolo R Int J Clin Pharmacol Ther; 2013 Feb; 51(2):141-6. PubMed ID: 23253950 [TBL] [Abstract][Full Text] [Related]
16. An introduction to nucleoside and nucleotide analogues. Squires KE Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469 [TBL] [Abstract][Full Text] [Related]
17. Antiretroviral combination therapy for HIV infection. Lewis DA Dent Update; 2003 Jun; 30(5):242-7. PubMed ID: 12861761 [TBL] [Abstract][Full Text] [Related]
18. [Non-nucleoside reverse transcriptase inhibitors]. Joly V; Yeni P Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953 [TBL] [Abstract][Full Text] [Related]